Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1989-9-1
pubmed:abstractText
The specificities of serum and intestinal antibodies from coeliac and normal individuals towards gluten-derived peptides, known to be toxic in coeliac disease, has been investigated. Though untreated coeliacs had high serum antibody levels towards gliadin and some gluten-derived peptides, antibody specificities to various toxic gluten-derived peptides were similar to normal patients. Further, no significant binding in any patient group was found to the alpha-gliadin-derived peptides B1342 (Wieser, Belitz & Ashkenazi, 1984) or the 12 amino-acid A-gliadin peptide (Kagnoff, 1985). There appears to be no direct relationship between the toxicities and the antigenic reactivity of gluten-derived peptides. Thus, the intestinal damage in coeliac disease is probably not primarily caused by antibody-dependent mechanisms. The specificities of several monoclonal antibodies which bound to wheat prolamins as well as prolamins from other coeliac-toxic cereals have also been investigated with these toxic gluten-derived peptides, in order to identify possible common epitopes. No monoclonal antibody tested bound the B1342 and 12-amino-acid A-gliadin peptide. However the monoclonal antibodies which were specific for the coeliac-toxic cereal prolamins did show the strongest binding to other coeliac-toxic gluten-derived peptides.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-1000854, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-13292281, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-13824666, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-2822550, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-2957394, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-3013966, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-3516457, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-3652513, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-3710610, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-3775259, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-3937222, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-4064561, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-4448408, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-4455563, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-4710813, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-507902, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-6358363, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-6524078, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-6604938, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-6692666, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-6744673, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-674547, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-6992088, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-7166001, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-7450439, http://linkedlifedata.com/resource/pubmed/commentcorrection/2752594-959100
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0009-9104
pubmed:author
pubmed:issnType
Print
pubmed:volume
76
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
384-90
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Anti-gliadin antibody specificity for gluten-derived peptides toxic to coeliac patients.
pubmed:affiliation
Division of Plant Industry, North Ryde, Australia.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't